FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.

FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases. is a phase 2, interventional study registered as NCT07515963 by Zhongnan Hospital, with a registry enrolment figure of 24 participants, started 2026-06-01 and due to reach its primary completion in 2027-02-01. Interventions recorded: FULIRI combination targeted therapy. Conditions listed: Colo-rectal Cancer. Primary outcome: Objective Response Rate (ORR). Colorectal eligibility wording from the registry: "\- (1) Age 18-75 years; (2) Histologically confirmed colorectal adenocarcinoma; (3) Synchronous liver metastasis of colorectal cancer, or liver metastasis occurring after curative surgery for colorectal cancer, and no prior systemic anti-tumor treatment (including but not limited to systemic chemoth". Sites: China. No results are recorded here; the registry entry is the source.